Loading clinical trials...
Loading clinical trials...
Part 1: An Open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin- Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity. Part 2: A Randomized, Double Blind, 12-weeks Parallel Group Study to Compare Effects of Aliskiren 300 mg and Amlodipine 5 mg on the RAS and Lipid/Carbohydrate Metabolism in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity
Conditions
Interventions
Aliskiren
Amlodipine
+2 more
Locations
2
Germany
Novartis Investigative Site
Buch, Germany
Novartis Investigative Site
Hanover, Germany
Start Date
June 1, 2007
Primary Completion Date
March 1, 2012
Completion Date
March 1, 2012
Last Updated
September 10, 2014
NCT02417740
NCT07073820
NCT07480265
NCT06876233
NCT06062394
NCT06899815
Lead Sponsor
Novartis
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions